Protagenic Therapeutics, Inc.\new (PTIX) Free cash flow 2023–2026
Protagenic Therapeutics, Inc.\new (PTIX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$2.8MFY2026 · since FY2023: -$2.0M → -$2.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$2.8M | — |
| FY2024 | -$3.9M | -93.1% |
| FY2023 | -$2.0M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More PTIX financial trends
PTIX RevenuePTIX Net incomePTIX Net marginPTIX Gross profitPTIX Gross marginPTIX Operating incomePTIX Operating marginPTIX Operating cash flowPTIX Capital expendituresPTIX Return on equityPTIX Stock buybacksPTIX Dividends paidPTIX Total assetsPTIX Total liabilitiesPTIX Shareholders’ equityPTIX overview →